Retrospective and prospective analyses of the treatment of overanticoagulated patients

Pharmacotherapy

Volumn 18, Issue 6 I, 1998, Pages 1264-1270

  Duong, Thu Mai ^a   Plowman, Brian K ^a   Morreale, Anthony P ^a   Janetzky, Katherine ^a  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHYTOMENADIONE; VITAMIN K GROUP; WARFARIN;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS;

AGED; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; HEMOSTATICS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VITAMIN K; WARFARIN;

EID: 0031725799     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Hirsh J, Dalen JE, Deykin D, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995;108(4):231-46S.
2. 1) compared with warfarin discontinuation. Blood Coagul Fibrinol 1993;4:739-41.
3. 1. Thromb Haemost 1992;67(1):13-15.
4. Shetty HGM, Fennerty AG, Routledge PA. Clinical pharmacokinetic considerations in the control of oral anticoagulation therapy. Clin Pharmacokinet 1989;16:238-53.
5. Stultz BM, Dere WH, Caine TH. Long term anticoagulation: indication and management. West J Med 1989;151:414-29.
6. Stein PD, Alpert JS, Copeland J, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1995;108(4):371-9S.
7. Vongpatanasin W, Hillis D, Lange RA. Prosthetic heart valves. N Engl J Med 1996;335(6):407-16.
8. Wood AJ. Management of venous thromboembolism. N Engl J Med 1996;335(24):1816-28.
9. Hirsh J. Optimal intensity and monitoring warfarin. Am J Cardiol 1995;75:39B-42.
10. Levine M, Raskob GE, Landefeld CS, et al. Hemorrhagic complications of anticoagulant treatment. Chest 1995;108(4): 276S-90.
11. Launbjerg J, Egeblad H, Heaf J, et al. Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients. J Intern Med 1991; 229:351-5.
12. Glover JJ, Morrill GB. Conservative treatment of over-anticoagulated patients. Chest 1996;108(4):987-90.
13. Brown WJ. Reversing the anticoagulant effect of warfarin with phytonadione: what is the right dose? Hosp Pharm 1996;31(8):953-4.
14. 1: an option to reduce warfarin's activity. Ann Pharmacother 1995;29:1228-31.
15. Becker RC, Ansell J. Antithrombotic therapy - an abbreviated reference for clinicians. Arch Intern Med 1995;155:149-61.
16. 1 in relation to anticoagulant poisoning. Br J Clin Pharmacol 1984;18:655-62.
17. 1. Ann Intern Med 1997;125:959-62.
18. Palareti G, Legnani C. Warfarin withdrawal - pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet 1996;30(4):300-13.
19. O'Reilly RA. Vitamin K and oral anticoagulant drugs as competitive antagonists in man. Pharmacology 1972;7:149-58
20. Wells PS, Holbrook AM, Crowther NR, et al. Interactions of warfarin with drugs and food. Ann Intern Med 1994;121(9): 676-82.
21. Kerin NZ, Blevins RD, Goldman L, et al. The incidence, magnitude, and time course of the amiodarone-warfarin interaction. Arch Intern Med 1988;148:1779-81.